BOSTON – (February 3, 2015) – Joslin Diabetes Center announced today that Insulet Corporation (NASDAQ: PODD), has joined the Joslin Institute for Technology Translation (JITT) as a Founding Member.
JITT, an innovation group at Joslin, is focused on leveraging the potential of technology with the introduction of clinical solutions, decision support tools and the advancement of digital health to improve the lives of people with diabetes.
Insulet Corporation is a medical device company based in Billerica, Massachusetts. It was founded in 2000 with the mission of making the lives of people with diabetes easier, specifically through its revolutionary tubeless OmniPod Insulin Management System.
“Our patients are always interested in new innovative solutions and the OmniPod System is an example of that,” said Howard Wolpert, M.D., Director of the Insulin Pump and Continuous Glucose Monitoring Programs at Joslin and Associate Professor of Medicine at Harvard Medical School. “We are excited to have Insulet as a Founding Member and look forward to collaborating with them around improving care for people with diabetes.”
“We are very pleased to welcome Insulet to the Joslin Institute for Technology Translation (JITT),” said Harry Mitchell, Executive Director of JITT. “We are eager to work with the Insulet Team in furthering our joint goal of advancing diabetes care.”
“Insulet is pleased to partner with the JITT to further our shared mission of improving the lives of people living with diabetes,” said Patrick Sullivan, President and Chief Executive Officer of Insulet. “We are committed to making diabetes a smaller part of life for all people affected and our collaboration with the esteemed Joslin Diabetes Center will certainly benefit this concentrated effort.”
Joslin Diabetes Center and the Joslin Institute for Technology Translation do not promote or endorse any product. Revenue and fees received by JITT will be invested in digital health to improve patient care.